
Systems biology approaches in the vaccine development – via Nature.com
The possibilities for personalised vaccines in all types of cancer are revealed today in a lecture from Dr Harpreet Singh at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.
“One of the biggest hurdles in cancer immunotherapy is the discovery of appropriate cancer targets that can be recognised by T-cells,” said Singh, who is scientific coordinator of the EU-funded GAPVAC phase I trial which is testing personalised vaccines in glioblastoma, the most common and aggressive brain cancer. “In the GAPVAC trial we will treat glioblastoma patients with vaccines that are ideal for each patient because they contain personalised antigens.”1
For all patients in the GAPVAC study, researchers will identify genes expressed in the tumour, peptides presented on the human leukocyte antigen (HLA) receptor (i.e. peptides which will be seen by T-cells), cancer specific mutations, and the ability of the immune system to mount a response to certain antigens. Based on this information, two vaccines, called actively personalised vaccines (APVACs), will be constructed and administered following conventional surgery.
The first vaccine will be prepared from a warehouse of 72 targets previously identified by the researchers as relevant for treatment in glioblastoma. These peptides have been manufactured and put on the shelf ready to be vaccinated in patients. Patients will be given a cocktail of the peptides they express and which their immune system can mount a response to.
Singh said: “A patient may express 20 of these 72 targets on their tumour, for example. If we find that the patient’s immune system can mount responses to 5 of the 20 targets, we mix the 5 peptides and give them to the patient. We mix the peptides off the shelf but the cocktail is changed for each patient because it is matched to their biomarkers.”
The second vaccine is synthesised de novo based on a mutated peptide expressed in the tumour of the patient. Singh said: “That peptide is not in our warehouse because it just occurs in this one single patient. The patient receives APVAC-1 and APVAC-2 in a highly personalised fashion in a way that I think has never been done for any patient.”
He added: “GAPVAC has two major goals. One is to show that personalised vaccines are feasible, since this is one of the most complicated trials ever done in cancer immunotherapy. The second is to show that we can mount far better biological responses in these patients compared to vaccination with non-personalised antigens.”
Singh’s previous research has shown that vaccination with non-personalised antigens leads to better disease control and longer overall survival in phase I and phase II clinical studies in patients with renal cell cancer.2
Singh said: “For the non-personalised vaccines we used off-the-shelf peptide targets that were shared by many patients with a particular cancer. Using this approach we have successfully vaccinated patients with renal cell cancer, colorectal cancer and glioblastoma.”
He added: “During this research we identified other targets that appeared in very few patients or even, in extreme cases, in a single patient. Often these rarer peptides are of better quality, meaning they are more specifically seen in cancer cells and occur at higher levels. This led us to start developing personalised cancer vaccines which contain the ideal set of targets for one particular patient. We hope they will be even more effective than the off-the-shelf vaccines.”
The Latest on: Personalised Vaccines
[google_news title=”” keyword=”Personalised Vaccines” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Personalised Vaccines
- These Are the RSV Vaccine Side Effects in Older Adults, According to Doctorson September 28, 2023 at 10:01 am
The FDA notes that, in one of the clinical trials for the vaccine, two of the participants developed acute disseminated encephalomyelitis (ADEM), a rare type of inflammation that affects the brain and ...
- Inovio spinoff Geneos raises another $5M to advance therapeutic cancer vaccineson September 28, 2023 at 8:10 am
A Montgomery County biotherapeutics company developing personalized therapeutic cancer vaccines said Thursday it has completed its series A3 financing round with an additional investment of $5 million ...
- RSV Vaccine Side Effects in Older Adults: What’s Normal and What’s Noton September 28, 2023 at 4:30 am
New RSV vaccines are now available to help prevent serious infection in people over 60. Doctors explain the RSV vaccine and its side effects in older adults.
- Developing Personalized Cancer Neoantigen Vaccineson September 26, 2023 at 1:01 am
Vaccibody has developed a unique platform technology able to substantially potentiate vaccines by an inherent mechanism that attract, activate and deliver antigens to antigen presenting cells.
- Personalized Vaccine and T Cell Therapy for Ovarian Cancer Patientson September 24, 2023 at 3:02 am
The combination of the personalized cancer vaccine with ACT led to ovarian cancer control in few patients within a span of three months, stated study results.
- Ovarian Cancer Patients Can Benefit From Personalised Vaccine, Adoptive T Cell Therapy: Studyon September 23, 2023 at 10:13 am
(MENAFN- IANS) New York, Sep 23 (IANS) Combining the personalised cancer vaccine with adoptive T cell therapy (ACT) can benefit patients with late-stage, drug-resistant ovarian cancer, a new study has ...
- Vaccines for Cancer? Scientists Are Making Progresson September 22, 2023 at 12:57 pm
But researchers are also studying vaccines as a way to treat cancer once it has already occurred or to prevent it from coming back. Just as vaccines train the body’s immune syst ...
- ACT and personalized cancer vaccine combo shows efficacy in ovarian cancer patientson September 22, 2023 at 12:20 am
A Ludwig Cancer Research study has shown that combining adoptive T cell therapy (ACT) with an innovative, personalized cancer vaccine under development at the Lausanne Branch of the Ludwig Institute ...
- Personalized cancer vaccine and adoptive T cell therapy benefits patients with advanced ovarian cancer: Studyon September 21, 2023 at 9:05 am
A Ludwig Cancer Research study has shown that combining adoptive T cell therapy (ACT) with an innovative, personalized cancer vaccine under development at the Lausanne Branch of the Ludwig Institute ...
- Combination of cancer vaccine and T cell therapy benefits patients with advanced ovarian canceron September 20, 2023 at 5:00 pm
A study has shown that combining adoptive T cell therapy (ACT) with an innovative, personalized cancer vaccine under development can benefit patients with late-stage, drug-resistant ovarian cancer.
via Bing News